The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Treatment pattern and prognosis in Japanese patients with metastatic renal cell carcinoma (mRCC) with favorable or intermediate MSKCC risk factors in the era of molecular targeted therapy.
Nobuo Shinohara
Consultant or Advisory Role - Novartis; Pfizer
Honoraria - Novartis; Pfizer
Satoru Maruyama
No relevant relationships to disclose
Wataru Obara
No relevant relationships to disclose
Katsunori Tatsugami
No relevant relationships to disclose
Sei Naito
No relevant relationships to disclose
Tomomi Kamba
No relevant relationships to disclose
Seiji Naito
No relevant relationships to disclose